Form 4: Sarepta CFO Sells Shares for Tax Obligations

Sarepta Therapeutics' Chief Financial Officer, Ryan Ho-Yan Wong, disposed of 327 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Ryan Ho-Yan Wong, Chief Financial Officer of Sarepta Therapeutics, Inc. (SRPT), disposed of 327 shares of common stock.
• The transaction occurred on July 31, 2025, at a price of $16.42 per share.
• The shares were sold by the company to satisfy tax withholding obligations associated with the vesting of restricted stock units granted on July 30, 2021.
• Following this transaction, Mr. Wong beneficially owns 17,328 shares of Sarepta Therapeutics common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax purposes related to equity compensation. It does not indicate positive or negative sentiment regarding the company's future prospects.

Industry Context

This is a routine insider transaction related to equity compensation and tax obligations, common across all industries for executives receiving restricted stock units. It does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Minimal direct impact on shareholders as it is a small, non-discretionary transaction for tax purposes.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of a small number of shares by the CFO to cover tax obligations related to RSU vesting. Such transactions are common and do not reflect the insider's view on the company's future performance. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based on the neutrality of this specific filing.

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Transaction, CFO, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Compensation